These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 25239059

  • 1. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial.
    Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A, Japan Febrile Neutropenia Study Group.
    J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059
    [Abstract] [Full Text] [Related]

  • 2. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
    Arnold HM, McKinnon PS, Augustin KM, Hladnik LM, Casabar E, Reichley RM, Dubberke ER, Westervelt P, Ritchie DJ.
    Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
    [Abstract] [Full Text] [Related]

  • 3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M.
    Scand J Infect Dis; 2004 Aug; 36(8):593-600. PubMed ID: 15370671
    [Abstract] [Full Text] [Related]

  • 4. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC, File TM, Embil JM, Krige JE, Klein S, Rose A, Melnick D, Soto NE.
    Surg Infect (Larchmt); 2005 Aug; 6(3):269-82. PubMed ID: 16201937
    [Abstract] [Full Text] [Related]

  • 5. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A, Strohmeyer M, Corti G, Buonomini MI, Franchino L, Romanelli G, Moretti AM, De Vizzi GB, Petraglia A, Mancini P, Atzeni R, Fogliani V, Giura R, Paradisi F.
    Drugs Exp Clin Res; 1999 Aug; 25(6):243-52. PubMed ID: 10713862
    [Abstract] [Full Text] [Related]

  • 6. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
    Biron P, Fuhrmann C, Cure H, Viens P, Lefebvre D, Thyss A, Viot M, Soler-Michel P, Rollin C, Grès JJ.
    J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A, Meli EZ, Mazzocchi P, Speranza V.
    Scand J Infect Dis; 1997 Oct; 29(5):503-8. PubMed ID: 9435041
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.
    Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, Romand JA, Bille J, Aymon D, Stratchounski L, Krawczyk L, Rubinstein E, Schaller MD, Chiolero R, Glauser MP, Cometta A, Cefepime Study Group,.
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.
    Fournier A, Eggimann P, Pagani JL, Revelly JP, Decosterd LA, Marchetti O, Pannatier A, Voirol P, Que YA.
    Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084
    [Abstract] [Full Text] [Related]

  • 14. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B, Malmborg AS, Tunevall G, Lindgren V, Bergman L, Mentzing LO, Nyström PO, Anséhn S, Bäckstrand B, Skau T.
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP, Herring AH, Benjamin DK, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB, Best Pharmaceuticals for Children Act-Pediatric Trials Network.
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients?
    Raad II, Abi-Said D, Rolston KV, Karl CL, Bodey GP.
    Cancer; 1998 Jun 15; 82(12):2449-58. PubMed ID: 9635539
    [Abstract] [Full Text] [Related]

  • 20. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE, Holloway WJ, Geckler RW.
    Clin Infect Dis; 1995 Jul 15; 21(1):86-92. PubMed ID: 7578765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.